Foremost Companies in the Immunohistochemistry Market: F. Hoffman-La Roche Ltd (Switzerland) and Danaher Corporation (US)

The global immunohistochemistry market is projected to reach USD 5.2 billion by 2029 from USD 3.7 billion in 2024, at a CAGR of 7.2% during the forecast period. Factors such as the growing geriatric population, rising prevalence of cancer, technological advancements in immunohistochemistry (IHC) technology, reimbursement policies for immunohistochemistry (IHC) tests, and the adoption of digital pathology are driving the growth of the immunohistochemistry (IHC) market. However, the high degree of consolidation is expected to restrain the market’s growth during the forecast period. A lack of standardization is a major challenge to the growth of this market.

The global immunohistochemistry market is highly competitive. Prominent players operating in the global immunohistochemistry market include @F. Hoffman-La Roche Ltd (Switzerland), Danaher Corporation , and 安捷伦 . The key players in this market are increasingly focusing on strategic expansions, partnerships, and product launches and approvals to expand their product and geographic footprint and increase market presence.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121632939

F. Hoffmann-La Roche AG (Switzerland)

Hoffmann-La Roche AG (Switzerland) is a biotechnology company focusing on the development and manufacturing of pharmaceutical and diagnostic products. Within the immunohistochemistry (IHC) market, Roche operates through its Pathology Lab segment, part of the Diagnostics Division. The company offers a wide range of IHC products, including the BenchMark ULTRA IHC/ISH System and the OptiView DAB IHC Detection Kit (OptiView). Roche has strengthened its position as a key market player through product launches, including both new and improved products with expanded application bases. Roche has added several products to its portfolio, such as the BenchMark ULTRA PLUS system launched in June 2022, VENTANA DP 600 slide scanner launched in June 2022, Elecsys anti-p53 Immunoassay launched in April 2021, and VENTANA ALK (D5F3) CDx Assay launched in March 2021 to strengthen its IHC offerings. Additionally, the company has received product approvals for new primary antibodies and the VENTANA MMR RDx systems for various disease applications. Roche maintains a global presence across Europe, the Middle East & Africa, North America, Asia Pacific, and Latin America.

Danaher Corporation (US) is a science and technology company specializing in the design, manufacture, and distribution of medical, industrial, and commercial products and services. Through its subsidiary Leica Biosystems, under the Anatomical Pathology Diagnostics and Core Lab Diagnostics segments, Danaher offers various chemical and immuno-staining instruments, reagents, and consumables. Key factors contributing to the company's market leadership include its wide customer base, use of advanced technology-enabled solutions, substantial investment in research and development (R&D), and comprehensive quality product lines. For instance, in 2023 the company invested USD 1.50 billion in research and development.

These R&D investments support the development of new products and improve the existing ones' functionality, effectiveness, ease of use, and reliability. The company also collaborates with research institutions, universities, and clinicians worldwide to develop better technologies and products. For instance, in June 2024, Leica Biosystem Nussloch GmbH, a subsidiary of Danaher Corporation partnered with Navinci (Sweden) to advance cancer research using automated in situ proximity ligation assays on the BOND RX Fully Automated Research Stainer. Additionally, in November 2022, Leica Biosystems Nussloch GmbH acquired Cell IDx, Inc., an immunodiagnostic company specializing in chromogenic and fluorescent multiplex IHC biomarker profiling products. These developments strengthen Danaher's competitive position in the IHC market.

Agilent Technologies, Inc. (US) is a major player in the life sciences, diagnostics, and applied chemical markets, providing application-focused solutions including instruments, software, services, and consumables for laboratory workflows in food, environmental, forensics, pharmaceutical, diagnostic, chemical & energy, and research fields. Agilent operates in the IHC market through Pathology Solutions, part of its Diagnostics and Genomics segment, offering IHC products for cancer diagnostics and anatomic pathology workflows.

In January 2024, Agilent partnered with Incyte (US) to develop companion diagnostic solutions for oncology and hematology, expanding its portfolio with novel biomarkers. Similarly, in January 2023, Agilent collaborated with Akoya Biosciences to develop chromogenic and immunofluorescent multiplex assays for immunohistochemistry diagnostic solutions. Agilent is also expanding in both developed and developing regions. In 2022, the company established a Center for Excellence (CoE) in India to innovate new products for analytical chemistry, biopharmaceuticals, and life science research. Agilent has a global presence, including in the US, UK, Australia, China, Germany, Italy, Malaysia, Singapore, Belgium, Denmark, Japan, and the Netherlands.

Buy Immunohistochemistry (IHC) Industry Report (414 Pages PDF with Insightful Charts, Tables, and Figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=121632939

Frequently Asked Questions (FAQs) of Immunohistochemistry (IHC) Market:

Who are the key players in the Immunohistochemistry market?

Key players in the Immunohistochemistry market include Hoffmann-LA-Roche AG (Switzerland), Danaher Corporation (US), Agilent Technologies Inc. (US), Merck KGAA (Germany), Thermo Fisher Scientific Inc. (US).

What are the drivers and opportunities for the Immunohistochemistry market?

The growth of the Immunohistochemistry market can be attributed to the rising geriatric population and growing prevalence of cancer disease to influence positive market growth, technological advancements in IHC, availability of reimbursements for IHC tests, and adoption of digital pathology. Also, Increasing demand for personalized medicine, growing significance of companion diagnostics, growth opportunities in emerging countries, application of AI in IHC.

Which product segment dominated the immunohistochemistry market?

antibodies product segment dominated the immunohistochemistry market which accounted for largest share. Antibodies and Kits segment are seen to be the leading segment with respect to the growth rate during the forecast period as a result of wide applications of monoclonal antibodies in the diagnosis and research of cancer, autoimmune disorders and infectious diseases combined with subsequent rise in the chronic diseases

Which application segment of the global immunohistochemistry market is expected to witness the highest growth?

The Diagnostic application segment dominated this market in 2022 and is estimated to register the highest growth during the forecast period. The growth of this segment is majorly accredited to elements such as the benefits of IHC over traditionally used special enzyme staining techniques that identify only a limited number of proteins, enzymes, and tissue structures.

What is the total CAGR expected to be recorded for the immunohistochemistry market from 2023-2028?

The CAGR is expected to record a CAGR of 7.4% from 2023-2028.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=121632939